Gastroenterology General Medicine Infectious Disease Strong — WHO-endorsed for use in resource-limited settings; validated in HCV
AST to Platelet Ratio Index (APRI)
Non-invasive marker of hepatic fibrosis and cirrhosis, most validated in chronic hepatitis C. Also used in NAFLD, hepatitis B, and alcoholic liver disease.
References
- Wai CT, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518–526.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Drugs
- Spironolactone (Ascites / Cirrhosis) · Aldosterone Antagonist / Potassium-Sparing Diuretic
- Furosemide (Ascites / Cirrhosis) · Loop Diuretic
- Entecavir · Antiviral — Hepatitis B (Nucleoside Analogue)
- Tenofovir (TDF/TAF) · Antiviral — Hepatitis B (Nucleotide Analogue)
- Glecaprevir / Pibrentasvir · Antiviral — Hepatitis C (Pan-Genotypic DAA)
- Sofosbuvir / Velpatasvir · Antiviral — Hepatitis C (Pan-Genotypic DAA)
Pathways
- Upper GI Bleeding · BSG Guidelines 2019; NICE NG141
- Lower Gastrointestinal Bleed · NICE; BSG; ACPGBI — Commissioning Guide
- Acute Pancreatitis · NICE; IAP/APA; ACPGBI — CG104
- Sepsis Screening and Sepsis Six · UK Sepsis Trust; NICE NG51; Surviving Sepsis Campaign 2021
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Isoniazid (INH) overdose · TOXBASE/NPIS; AACT/EAPCCT; BNF
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.